Table 2. Crude and weighted 3- and 5-year risk differences and risk ratios comparing postoperative 5-FU/capecitabine alo vs. no postoperative chemotherapy and all-cause and cancer-specific mortality.
| Outcome risk | ||||||||
|---|---|---|---|---|---|---|---|---|
|
|
||||||||
| Outcome | Subgroup | Crude/Weighted and time period | No postoperative chemotherapy | Postoperative 5-FU/capecitabine alone | Risk difference | 95% CI | Risk ratio | 95% CI |
| All-cause mortality | Age 66-74 years | Crude | ||||||
| 3-year | 0.23 | 0.12 | -0.11 | (-0.18, -0.05) | 0.51 | (0.32, 0.80) | ||
| 5-year | 0.34 | 0.13 | -0.21 | (-0.29, -0.13) | 0.39 | (0.25, 0.61) | ||
| Age 75+ years | Crude | |||||||
| 3-year | 0.25 | 0.28 | 0.03 | (-0.06, 0.12) | 1.12 | (0.79, 1.58) | ||
| 5-year | 0.41 | 0.42 | 0.01 | (-0.10, 0.12) | 1.02 | (0.78, 1.34) | ||
| Age 66-74 years | Weightedb | |||||||
| 3-year | 0.25 | 0.12 | -0.14 | (-0.23, -0.04) | 0.46 | (0.28, 0.76) | ||
| 5-year | 0.36 | 0.13 | -0.23 | (-0.33, -0.12) | 0.37 | (0.23, 0.60) | ||
| Age 75+ years | Weightedb | |||||||
| 3-year | 0.22 | 0.28 | 0.05 | (-0.05, 0.16) | 1.24 | (0.81, 1.91) | ||
| 5-year | 0.39 | 0.42 | 0.03 | (-0.10, 0.16) | 1.07 | (0.77, 1.49) | ||
| Cancer-specific mortality | Age 66-74 years | Crude | ||||||
| 3-year | 0.12 | 0.07 | -0.05 | (-0.11, 0.01) | 0.59 | (0.30, 1.16) | ||
| 5-year | 0.19 | 0.11 | -0.08 | (-0.17, 0.01) | 0.58 | (0.25, 1.33) | ||
| Age 75+ years | Crude | |||||||
| 3-year | 0.15 | 0.20 | 0.05 | (-0.05, 0.15) | 1.34 | (0.75, 2.39) | ||
| 5-year | 0.22 | 0.23 | 0.01 | (-0.12, 0.14) | 1.05 | (0.56, 1.97) | ||
| Age 66-74 years | Weightedb | |||||||
| 3-year | 0.18 | 0.07 | -0.11 | (-0.29, 0.06) | 0.39 | (0.13, 1.16) | ||
| 5-year | 0.24 | 0.11 | -0.13 | (-0.29, 0.04) | 0.46 | (0.17, 1.28) | ||
| Age 75+ years | Weightedb | |||||||
| 3-year | 0.16 | 0.20 | 0.03 | (-0.09, 0.15) | 1.20 | (0.59, 2.43) | ||
| 5-year | 0.25 | 0.23 | -0.02 | (-0.17, 0.14) | 0.93 | (0.46, 1.88) | ||
Abbreviations: CI=confidence interval
a
Standard error based on standard deviation of 200 nonparametric bootstrap resamples.
b
Weighted for age, sex, race/ethnicity, AJCC pathologic stage, cancer site, marital status, metropolitan residence, census tract poverty level (%), congestive heart failure, peripheral vascular disease, cerebrovascular disease, COPD, diabetes without sequelae, diabetes with sequelae, renal disease, 30-days post-operative hospitalization, preoperative therapy (chemoradiation or radiation therapy alone), predicted probability of ADL-D.